Abstracts tagged "Mortality"

Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Mohanad Elfishawi¹, Mahmut Kaymakci¹, Sara Achenbach², Cynthia Crowson¹, Tanaz Kermani³, Cornelia M. Weyand⁴, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of California Los Angeles, Los Angeles, CA, ⁴Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
Abstract Number: 0127 • ACR Convergence 2023
Time Trends, Cumulative Incidence, and Impact on Survival of Interstitial Lung Disease in Systemic Sclerosis: Results from a Population-based Cohort Study
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Cardiopulmonary complications are the number one cause of mortality in Systemic sclerosis (SSc). We studied the prevalence, cumulative incidence, predictors and impact of interstitial…
Abstract Number: 0762 • ACR Convergence 2023
Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction
Magdalena Harasimowicz¹, Deborah Stone², Manuel Carpio Tumba¹, Tina Romeo², Urekha Karri¹, Patrycja Hoffmann³, Helen Leavis⁴, Alexander Miethke⁵, Theo Heller², Anjali Rai², Ivona Aksentijevich², amanda ombrello⁶, Daniel Kastner⁷ and Daniella Schwartz¹, ¹University of Pittsburgh, Pittsburgh, PA, ²NIH, Bethesda, MD, ³NIH, Vienna, VA, ⁴Infection Immunity Utrecht, Utrecht, Netherlands, ⁵Cincinnati Children's Hospital, Cincinnati, OH, ⁶National Institutes of Health, Rockville, MD, ⁷National Human Genome Research Institute, Bethesda, MD
Background/Purpose: Heterozygous loss-of-function TNFAIP3 mutations cause A20 haploinsufficiency (HA20), an early-onset immune dysregulatory disease1. While HA20 was initially described as an inherited form of Behcet’s…
Abstract Number: 1399 • ACR Convergence 2023
Trends in Proportionate Cardiovascular Mortality in Patients with Ankylosing Spondylitis in the Era of Biologic Therapies: Analysis of US Death Certificate Data
Ansaam Daoud¹, Sadeer Al-Kindi² and Marina Nighat Magrey³, ¹University Hospitals, Case Western Reserve University, Akron, OH, ²Case Western Reserve University/University Hospitals, Cleveland, OH, ³Case Western Reserve University, University Hospitals, Cleveland, OH
Background/Purpose: Ankylosing Spondylitis (AS) is associated with an increased risk of cardiovascular disease, partly due to systemic inflammation, and an increased risk of vascular mortality.…
Abstract Number: 1817 • ACR Convergence 2023
Geographic Variability of Inflammatory Bowel Disease Related Mortality, 1999-2019; CDC WONDER
Saleha Aziz¹, Anum Akhlaq¹, Sana Gurz² and Yousaf Zafar¹, ¹University of Mississippi Medical Center, Jackson, MS, ²University of Nevada, Las Vegas, NV
Background/Purpose: The United States makes a significant contribution to Inflammatory Bowel Disease (IBD) related disease burden worldwide. However, data on geographic variability of IBD related…
Abstract Number: 2428 • ACR Convergence 2023
Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors
Natalie McCormick¹, Kehuan Lin², Chio Yokose³, Na Lu⁴, Yuqing Zhang¹ and Hyon K. Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: A recent UK study reported a transient increased cardiovascular risk after gout flare episodes [Cipolletta et al. JAMA 2022], which may translate to premature…
Abstract Number: 0129 • ACR Convergence 2023
Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020)
Anukul Karn¹, Sara Achenbach², Alicia Hinze³, Cynthia Crowson¹ and Ashima Makol², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic - Rochester, MN, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a rare chronic inflammatory disease characterized by immune-mediated dysfunction, vasculopathy and widespread internal organ fibrosis; and the highest case fatality…
Abstract Number: 0772 • ACR Convergence 2023
MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jacob Klein¹, Austin Wheeler¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, K Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Dana Ascherman⁶, Gary Kunkel⁷, Grant Cannon⁸, Paul Monach⁹, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls¹⁰ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The gain of function MUC5B rs35705950 promoter variant is the strongest genetic risk factor for the development of RA-ILD (specific to a usual interstitial…
Abstract Number: 1466 • ACR Convergence 2023
Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020
Shreena Kamlesh Gandhi¹, Abhiram Challa², Sandhya Shri Kanniyaram³, Arnav Kamat⁴, Tejasri Polana⁵ and Kaleb Michaud⁶, ¹Kansas University School of Medicine, Wichita, KS, ²KU School of Medicine, Wichita, KS, ³John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ⁴NYCH+H/Woodhull, New York, NY, ⁵Jawaharlal Nehru Medical College, Belgaum, Belgaum, India, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: SLE patients are prone to hospitalizations and readmissions compared to general population. Depression is highly prevalent among patients with SLE and is an important…
Abstract Number: 1918 • ACR Convergence 2023
Nationwide Analysis of Predictors of Sarcoid Inpatient Mortality
Michael Manansala¹, Faria Sami², Shilpa Arora³ and Augustine Manadan¹, ¹Rush University Medical Center, Chicago, IL, ²John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ³Cook County Hospital, Chicago, IL
Background/Purpose: Sarcoidosis is multisystem autoimmune disease characterized by noncaseating granulomas which can result in significant morbidity and mortality. This study aims to identify variables associated…
Abstract Number: 2533 • ACR Convergence 2023
Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka², Eisuke Inoue³, Mai Abe¹, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai⁴, Rei Yamaguchi¹, Katsunori Ikari⁵, Ayako Nakajima⁶, Hisashi Yamanaka⁷ and Masayoshi Harigai⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjunku-ku, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Research Administration Center, Showa University, Shinagawa-ku, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine,, Shinjunku-ku, Japan, ⁵Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁶Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁷Sanno Medical Center, Tokyo, Japan, ⁸Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have been reported to have higher mortality rates than the general population. Our previous report showed that the standardized…
Abstract Number: 027 • 2023 Pediatric Rheumatology Symposium
Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa
Jessica Perfetto¹, Laura Lewandowski², Dawn Wahezi¹, Christiaan Scott³ and Angela Migowa⁴, ¹Children's Hospital at Montefiore, New York, NY, ²NIAMS, NIH, Bethesda, MD, ³Red Cross War Memorial Children's Hospital, ⁴Aga Khan University, Nairobi, Kenya
Background/Purpose: There is a paucity of data on pediatric rheumatic disease (PRD) in low and middle-income countries (LMIC), creating a false perception of low prevalence…
Abstract Number: 0101 • ACR Convergence 2022
Twenty-five Years of Mortality Data in Those with Lower Extremity Osteoarthritis: The Role of Socioeconomic Status
Cara Murphy¹, Rebecca Cleveland¹, Amanda Nelson², Yvonne Golightly³ and Leigh Callahan⁴, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: The purpose of this study is to explore the relationship between socioeconomic status (SES) measures (income, professional employment, block group poverty level, education level,…
Abstract Number: 1055 • ACR Convergence 2022
Associations of Potential Risk Factors with Severe Outcomes in Scleroderma Renal Crisis: Results from a Single Center Study
Alex Luta¹, Saloni Godbole¹ and Virginia Steen², ¹Medstar Georgetown University Hospital, Washington, DC, ²Georgetown University School of Medicine, Washington, DC
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe and life-threatening complication of Systemic Sclerosis (SSc). Given the rare nature of SSc, it is challenging to…
Abstract Number: 1873 • ACR Convergence 2022
Relationship Between Baseline Characteristics of Rheumatoid Arthritis and Types of Mortality: Study of Cohort Followed Prospectively
Cristina Corrales¹, Fabricio Benavides Villanueva¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Virgi Portilla⁴, Ricardo Blanco⁵, Miguel Ángel González-Gay⁶ and Alfonso Corrales⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of mortality mainly due to cardiovascular (CV) events, infections and malignancies. The relationship between the…

« Previous Page
1
…
7
8
9
10
11
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.